Our Take
A registry solves the recall problem but assumes data discipline across fractured supply chains; India's real test is enforcement, not architecture.
Why it matters
India implants more than a million high-risk devices yearly with no tracking mechanism. A registry uncovers safety gaps and builds local evidence for policy—but only if manufacturers, suppliers, and hospitals actually report.
Do this week
Medical device importers and hospital procurement teams: audit your cardiac and orthopaedic implant sourcing now before mandatory registry requirements force standardization on your supply chain.
India plans national implant registry to close tracking gaps
India will create a national registry to track implantable medical devices and patients, according to a senior government official cited by ET HealthWorld. The announcement is expected soon. The registry will mandate data maintenance for all cardiac and orthopaedic implants in the first phase, covering manufacturer, supplier, and hospital records, then expand to all devices in later phases.
More than a million high-risk implants are used annually in India, including cardiac stents, orthopaedic joints, pacemakers, and spinal devices. The sector is currently valued at $15 billion and projected to reach $50 billion by 2030 (per industry estimates). Cardiac stents top the list of devices associated with adverse events, though faulty knee and spinal implants have also surfaced.
Registry data will guide procurement policy for government-run schemes, distinguish quality devices from low-cost alternatives, and block cheap, low-quality imports from neighboring countries, the official said. The Association of Indian Medical Devices Industry sees the registry enabling rapid patient identification during global recalls and tracking real-world safety outcomes.
Regulatory gaps expose India to recall blind spots and counterfeit risk
India's medical implant sector has long faced regulatory fragmentation, import dependence, high costs, and weak specialized oversight. No current system can trace an implanted device back to a patient if a global recall occurs. This gap leaves patients at risk and complicates adverse event investigation.
The registry addresses two problems: first, it creates accountability from manufacturer to patient, making it possible to locate implant recipients during recalls; second, it builds an evidence base of real-world implant performance and failure modes in the Indian population, reducing reliance on imported clinical data and supporting locally-informed policy.
The timing follows the National Medical Devices Policy introduced in 2023, signaling sustained intent to tighten the sector. With the implant market growing fast and cheap imports a documented concern, the registry is a structural move to enforce quality standards at scale.
Who must prepare for mandatory reporting
Implant manufacturers, distributors, and hospital procurement teams should expect reporting obligations for cardiac and orthopaedic devices first. Success depends on three conditions: clear data standards (what fields hospitals must capture), simple submission pathways, and enforcement with teeth. Until those details arrive, assume your supply chain will be audited retroactively once the registry launches.
Hospitals should begin digitizing implant records now, linking device serial numbers to patient identifiers and procurement dates. Distributors should verify their upstream sourcing documentation, as the registry will surface unauthorized or counterfeit stock quickly. Importers of low-cost alternatives should expect increased scrutiny during the procurement review phase.